Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have displayed clinical significance reductions in the risk of heart failure hospitalizations. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss clinical trials using SGLT2is in patients with heart failure.
Dr Borlaug presented an abstract entitled ‘Evaluation Of The Mechanism Of Benefit For Dapagliflozin In Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial’ at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023
Click here to view Dr Borlaug’s video on the hemodynamic randomized trial
What have previous clinical trials taught us about sodium-glucose co-transporter 2 inhibitors (SGLT2i) and what questions remain unanswered? (0:17)
Disclosures: Barry Borlaug is a consultant for Aria, Boehringer Ingelheim, Edwards, Eli Lilly, Imbria, Merck and VADovations, and has received grant/research support from Astra Zeneca, Corvia, GlaxoSmith Kline, Medtronic, Mesoblast, NIH/NHLBI, Novo Nordisk and Tenax.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ACC 2023
Access more content on Heart Failure here
My name is Barry Borlaug. I’m a cardiologist and Professor of Medicine at Mayo Clinic in Rochester, Minnesota.
Q: What have previous clinical trials taught us about sodium-glucose co-transporter 2 inhibitors (SGLT2i) and what questions remain unanswered?
Well, it’s a good question. I mean, SGLT2 inhibitors were really discovered by serendipity because the FDA required large trials to show cardiovascular safety and they were serendipitously shown to reduce the risk of heart failure. That was then later tested prospectively in patients with heart failure with reduced ejection fraction, and then most recently in patients with heart failure with preserved ejection fraction (HFpEF).
And across the board, we have seen a significant and clinically meaningful reduction in the risk of heart failure hospitalizations, the combined endpoint of heart failure hospitalization and cardiovascular death. These drugs also improve quality of life and there’s some evidence that they improve functional capacity as well in patients with HFpEF. But like I said, they were discovered serendipitously. Although there is a lot of speculation about the mechanism of benefit, no one really knows and that’s an important sort of unmet need that we need to fill.
Subtitles and transcript are autogenerated
Share this Video
Related Videos In Heart Failure
ESC Congress 2023 Amsterdam: Ross Campbell, OPERA-AI trial, handheld echocardiography in suspected heart failure
Presented at the European Society of Cardiology Congress (ESC Congress) 2023 Amsterdam, the OPERA-AI trial compared the use of handheld echocardiography analysed by artificial intelligence (AI) to ‘cart-based’ echocardiography reported by humans, to help diagnose suspected heart failure. In this touchCARDIO interview, we speak to Dr. Ross Campbell (University of Glasgow, Glasgow, UK) to discuss the […]
ESC Congress 2023 Amsterdam: Robert Mentz, HEART-FID trial, intravenous iron for heart failure with reduced ejection fraction
The HEART-FID trial built on research from the AFFIRM-AHF and IRONMAN trials to investigate the use of intravenous iron in treating heart failure with iron deficiency. In this touchCARDIO interview, we speak to Dr. Robert Mentz (Duke University, NC, US) regarding the HEART-FID trial, presented at the European Society of Cardiology Congress (ESC Congress) 2023 […]
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]